U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07239323) titled 'In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies' on Nov. 16.
Brief Summary: This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory malignant hematological tumors.
It is an early exploratory clinical study of the safety, tolerability and initial efficacy in the treatment of relapsed or refractory malignant hematological tumors.
Study Start Date: July 01
Study Type: INTERVENTIONAL
Condition:
B-Acute Lymphoblastic Leukemia
B Cell Non-Hodgkin's Lymphoma
Multiple Myeloma
Intervention:
BIOLOGICAL: Invivo CAR-T
Patien...